In yesterday’s Wall Street session, Design Therapeutics Inc. (NASDAQ:DSGN) shares traded at $7.07, up 0.28% from the previous session.
As of this writing, 5 analysts cover Design Therapeutics Inc. (NASDAQ:DSGN). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $42.00 and a low of $6.00, we find $22.00. Given the previous closing price of $7.05, this indicates a potential upside of 212.06 percent. DSGN stock price is now -11.00% away from the 50-day moving average and -50.41% away from the 200-day moving average. The market capitalization of the company currently stands at $408.72M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
There are 0 analysts who have given it a hold rating, whereas 4 have given it a buy rating. Brokers who have rated the stock have averaged $22.60 as their price target over the next twelve months.
With the price target of $21, Wedbush recently initiated with Outperform rating for Design Therapeutics Inc. (NASDAQ: DSGN). On May 02, 2022, RBC Capital Mkts recently initiated its ‘Outperform’ rating on the stock quoting a target price of $30, while ‘Goldman’ rates the stock as ‘Sell’.
In other news, George Simeon, Director bought 40,000 shares of the company’s stock on Dec 20. The stock was bought for $325,432 at an average price of $8.14. Upon completion of the transaction, the Director now directly owns 6,526,476 shares in the company, valued at $46.14 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 20, 10% Owner SR One Capital Fund I Aggregat bought 40,000 shares of the business’s stock. A total of $325,432 was incurred on buying the stock at an average price of $8.14. This leaves the insider owning 6,526,476 shares of the company worth $46.14 million. Insiders disposed of 590,880 shares of company stock worth roughly $4.18 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DSGN stock. A new stake in Design Therapeutics Inc. shares was purchased by UBS GROUP AG during the first quarter worth $1,103,000. MARSHALL WACE, LLP invested $798,000 in shares of DSGN during the first quarter. In the first quarter, CUBIST SYSTEMATIC STRATEGIES, LLC acquired a new stake in Design Therapeutics Inc. valued at approximately $773,000. ACADIAN ASSET MANAGEMENT LLC acquired a new stake in DSGN for approximately $410,000. SILVERARC CAPITAL MANAGEMENT, LLC purchased a new stake in DSGN valued at around $403,000 in the second quarter. In total, there are 137 active investors with 72.10% ownership of the company’s stock.
Tuesday morning saw Design Therapeutics Inc. (NASDAQ: DSGN) opened at $7.18. During the past 12 months, Design Therapeutics Inc. has had a low of $6.08 and a high of $26.30. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 33.50, and a quick ratio of 33.50. The fifty day moving average price for DSGN is $7.88 and a two-hundred day moving average price translates $14.23 for the stock.
The latest earnings results from Design Therapeutics Inc. (NASDAQ: DSGN) was released for Sep, 2022.
Design Therapeutics Inc.(DSGN) Company Profile
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company’s portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
